Invasive Candidiasis

McCarty, Todd P; Pappas, Peter G.

doi:10.1016/j.idc.2015.10.013

Cited by 236 publications

(239 citation statements)

References 148 publications

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…It is responsible for 72.3% of all fungal infectious agents, followed by Candida krusei and Candida glabrata, Candida tropicalis and Candida parapsilosis. Moreover, other studies have also reported that Candida species were dominant pathogens [10]. However, in Taiwan and Korea, the most prevalent pathogens were Cryptococcus and Aspergillus, respectively [7,11].…”

Section: Discussionmentioning

confidence: 90%

Invasive Fungal Infection as the Initial Presentation of Systemic Lupus Erythematosus

Mel¹,

Sodqi²,

Jebbar³

et al. 2017

J Antimicrob Agents

View full text Add to dashboard Cite

Invasive fungal infections (IFI) are not frequently seen in systemic lupus erythematosus (SLE). However, when present they are very dangerous, being potentially fatal in the majority of cases. Immunosuppressive therapy is the strongest risk factor for IFI and correlates with death during infective episodes. However, IFI may reveal SLE in a patient without any precedent disease and in the absence of other causes of immunosuppression. We report a case of invasive pulmonary fungal infection (IPFI) revealing SLE. We report a new case of IFI revealing a SLE.

show abstract

Section: Discussionmentioning

confidence: 90%

Invasive Fungal Infection as the Initial Presentation of Systemic Lupus Erythematosus

Mel¹,

Sodqi²,

Jebbar³

et al. 2017

J Antimicrob Agents

View full text Add to dashboard Cite

show abstract

“…Candidemia now ranks as the third most common cause of health care-associated bloodstream infections (BSI) and is the leading cause of BSIs in intensive care units (ICUs) (3). Nevertheless, treatment of candidiasis, from superficial to invasive infections, still relies on a limited drug arsenal composed mainly of amphotericin B, triazoles (mostly fluconazole), and echinocandins (13).…”

Section: Resultsmentioning

confidence: 99%

Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors

Vila

Lopez-Ribot

2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Candida albicans remains the main causative agent of candidiasis, one of the most frequent nosocomial infections, with unacceptably high mortality rates. Biofilm formation is a major risk factor for invasive candidiasis, as Candida biofilms display high-level resistance to most antifungal agents. In this work we have screened the Pathogen Box chemical library (Medicines for Malaria Venture [MMV], Switzerland) in search for inhibitors of C. albicans biofilm formation. Our initial screen identified seven hits, and additional dose-response assays confirmed the biofilm-inhibitory activity of six of these small molecules. Three compounds, MMV688768, MMV687273, and MMV687807, were also able to reduce the metabolic activity of cells within preformed biofilms. Interestingly, the most potent of these, compound MMV688768, displayed increased antibiofilm activity compared to its activity against planktonic cultures, indicating that it may affect processes with a predominant role during the biofilm mode of growth. This compound demonstrated a high selectivity index when its antibiofilm activity was compared with its toxicity in liver hepatocellular cells. In vitro combination assays showed a synergistic interaction between compound MMV688768 and fluconazole against preformed biofilms. Overall, our results indicate that this compound may constitute a potential candidate for further clinical development.

show abstract

“…was indicated as one of the main etiological agents of BSIs, responsible for 7.6% of the cases 2 . Among the most common causes of BSIs is candidemia, which is the syndrome most frequently associated with invasive candidiasis 5 and high mortality rates (40% to 60%) 2 . Invasive candidiasis is one of the major clinical manifestations of the Candida genus caused by C. albicans and non-albicans 6 Candida, these, in turn, respond to at least 50% of the invasive infections by Candida spp.…”

mentioning

confidence: 99%

Candida Auris: Emergence and Epidemiology of a Highly Pathogenic Yeast

Santos¹,

Lana²,

Mezzari³

2017

Clin. Biomed. Res.

View full text Add to dashboard Cite

Candida auris is a multidrug-resistant emerging yeast, which was responsible for healthcare-associated infection outbreaks, and was cataloged as a new species in 2009, after being isolated from a patient's ear canal secretion in Japan. Since the notification of this first occurrence, numerous cases have been reported throughout the world, including Brazil. C. auris affects mainly inpatients, patients in intensive care units, exposed to broad-spectrum antifungal medications and who make use of vascular catheters. Currently, this yeast is one of the main responsible for invasive infections in hospitals and has been cause of concern by authorities and organs due to its rapid dissemination and difficult treatment caused by its low susceptibility to antifungal agents traditionally used in clinical practice. As a contributor to the severity of infections associated with C. auris, the transmission mechanism is still unknown, which implies in a lack of control of the microorganism and high mortality rates. Thus, this literature review presents relevant information in order to alert the importance of C. auris as an etiological agent of systemic infections, as well as its epidemiology and the real challenges of the treatment.

show abstract

Invasive Candidiasis

Cited by 236 publications

References 148 publications

Invasive Fungal Infection as the Initial Presentation of Systemic Lupus Erythematosus

Invasive Fungal Infection as the Initial Presentation of Systemic Lupus Erythematosus

Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors

Candida Auris: Emergence and Epidemiology of a Highly Pathogenic Yeast

Contact Info

Product

Resources

About